Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Sequential rituximab therapy sustains remission of nephrotic syndrome but carries high risk of adverse effects
Aditi Sinha, Georgie Mathew, Arushi Arushi, et al.
Nephrology Dialysis Transplantation (2022) Vol. 38, Iss. 4, pp. 939-949
Closed Access | Times Cited: 21

Showing 21 citing articles:

Childhood nephrotic syndrome
Marina Vivarelli, Keisha L. Gibson, Aditi Sinha, et al.
The Lancet (2023) Vol. 402, Iss. 10404, pp. 809-824
Closed Access | Times Cited: 42
Risk factors and retreatment for relapse in childhood primary nephrotic syndrome treated with rituximab
Yuanzhao Zhi, Lu Cao, Rui Gu, et al.
Pediatric Nephrology (2025)
Closed Access | Times Cited: 1
Secondary hypogammaglobulinemia in patients with multiple sclerosis on anti-CD20 therapy: Pathogenesis, risk of infection, and disease management
Enríque Alvarez, Erin E. Longbrake, Kottil Rammohan, et al.
Multiple Sclerosis and Related Disorders (2023) Vol. 79, pp. 105009-105009
Open Access | Times Cited: 22
Kinetic-pharmacodynamic model to predict post-rituximab B-cell repletion as a predictor of relapse in pediatric idiopathic nephrotic syndrome
Ziwei Li, Qian Shen, Hong Xu, et al.
Frontiers in Pharmacology (2025) Vol. 15
Open Access
Persistent Hypogammaglobulinemia After Rituximab Therapy in Pediatric Patients, Prevalence and Clinical Outcomes
Susanna P.C. Höppener, Saskia R. Veldkamp, Mark de Groot, et al.
Clinical Immunology Communications (2025)
Open Access
Anti-CD20 monoclonal antibodies for idiopathic nephrotic syndrome: Advances, challenges, and future directions
Andrea Angeletti, Gian Marco Ghiggeri
Pediatric Nephrology (2025)
Open Access
Age and memory B cells at baseline are associated with risk of relapse and memory B-cell reappearance following anti-CD20 treatment in pediatric frequently-relapsing/steroid-dependent nephrotic syndrome
Manuela Colucci, Andrea Angeletti, Federica Zotta, et al.
Kidney International (2023) Vol. 104, Iss. 3, pp. 577-586
Closed Access | Times Cited: 10
Repetitive administration of rituximab can achieve and maintain clinical remission in patients with MCD or FSGS
Thomas Osterholt, Polina Todorova, Lucas Kühne, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 8
Biologics in steroid resistant nephrotic syndrome in childhood: review and new hypothesis-driven treatment
Andrea Angeletti, Maurizio Bruschi, Xhuliana Kajana, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 8
Kidney outcomes in children with primary focal segmental glomerulosclerosis from a low- and middle- income country
Kolluri Priyanka, Bobbity Deepthi, Sudarsan Krishnasamy, et al.
Pediatric Nephrology (2024) Vol. 39, Iss. 12, pp. 3485-3495
Closed Access | Times Cited: 2
Combination of rituximab and low-dose glucocorticoids for idiopathic refractory nephrotic syndrome with MCD/FSGS: a single-center prospective cohort study
Aikeda Yimamuyushan, Youqi Li, Wenwen Jiao, et al.
Renal Failure (2024) Vol. 46, Iss. 2
Open Access | Times Cited: 2
Predictive factors of long-term disease remission after rituximab administration in patients with childhood-onset complicated steroid-dependent nephrotic syndrome: a single-center retrospective study
Rie Ohyama, Shuichiro Fujinaga, Koji Sakuraya, et al.
Clinical and Experimental Nephrology (2023) Vol. 27, Iss. 10, pp. 865-872
Closed Access | Times Cited: 5
Steroid-sensitive nephrotic syndrome in children
Olivia Boyer, Agnes Trautmann, Dieter Haffner, et al.
Nephrology Dialysis Transplantation (2022) Vol. 38, Iss. 5, pp. 1123-1126
Closed Access | Times Cited: 4
Japanese clinical practice patterns of rituximab treatment for minimal change disease in adults 2021: A web-based questionnaire survey of certified nephrologists
Masahiro Koizumi, Takuji Ishimoto, Sayaka Shimizu, et al.
PLoS ONE (2024) Vol. 19, Iss. 3, pp. e0299053-e0299053
Open Access
Predictors for Persistent Hypogammaglobulinemia After Rituximab Therapy in Pediatric Patients
Susanna P.C. Höppener, Saskia R. Veldkamp, Mark de Groot, et al.
Research Square (Research Square) (2024)
Open Access
Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children
Nicholas Larkins, Deirdré Hahn, Isaac D Liu, et al.
Cochrane library (2024) Vol. 2024, Iss. 11
Closed Access
Single (375 mg/m2) vs. double dose of rituximab along with mycophenolate mofetil for children with steroid-dependent/frequently relapsing nephrotic syndrome: a multicentre open-label randomized controlled trial
Rajiv Sinha, Subal Pradhan, Sumantra Raut, et al.
Pediatric Nephrology (2024)
Closed Access
Meta-analysis on the efficacy and safety of rituximab versus tacrolimus for nephrotic syndrome in the paediatric age group
Syeda Tayyaba Rehan, Eman Ali, Farea Eqbal, et al.
Clinical Kidney Journal (2023) Vol. 17, Iss. 1
Open Access | Times Cited: 1
Rituximab as a Maintenance Therapy in Pediatric Patients with Frequent-Relapsing or Steroid Dependent Nephrotic Syndrome: Efficacy, Safety, and Steroid Reduction
Xiaochuan Wu, Qiaoping Chen, Yan Cao, et al.
Research Square (Research Square) (2024)
Open Access
Determinants of the duration of B-cell depletion after rituximab in a pediatric population
Rayan Affes, Anne‐Laure Lapeyraque, C Laroche, et al.
Nephrology Dialysis Transplantation (2023) Vol. 39, Iss. 1, pp. 159-162
Closed Access
Rituximab

Reactions Weekly (2023) Vol. 1986, Iss. 1, pp. 390-390
Closed Access
Page 1

Scroll to top